Seelos Therapeutics shares are trading lower after the company announced that its ALS study with SLS-005 did not meet statistical significance in the primary and secondary endpoint in the Full Analysis Set.
Portfolio Pulse from Benzinga Newsdesk
Seelos Therapeutics' stock is trading lower following the announcement that its ALS study with SLS-005 failed to meet statistical significance in both primary and secondary endpoints in the Full Analysis Set.
March 19, 2024 | 1:24 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Seelos Therapeutics' shares are trading lower due to the failure of its ALS study with SLS-005 to achieve statistical significance in key endpoints.
The failure of the ALS study is a significant setback for Seelos Therapeutics, as it directly impacts the potential future revenue and growth prospects of SLS-005, a key product in their pipeline. This negative outcome is likely to diminish investor confidence and could lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100